About ALCMI

The Addario Lung Cancer Medical Institute (ALCMI) is a 501(c)(3) non-profit, public charity organization, with offices in California and Connecticut and member institutions in the US and Europe, dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. In response to widely-acknowledged and systematic barriers to progress against lung cancer, ALCMI developed and launched, as its inaugural research program, a targeted, multi-institutional biorepository. The purpose of this project is to facilitate application of the known biomarkers to patients presenting today, and to establish such a collection of biospecimens that will be essential for discovering and validating new biomarkers for improved diagnostics, treatments and cancer patient outcomes.

ALCMI is a participating member of FasterCures' TRAIN (The Research Acceleration and Innovation Network) which was established to identify and promote models of innovation and collaboration in medical research. FasterCures has created TRAIN and connected dozens of disease research organizations with results–oriented research methods; thus amplifying best practices and telling the story of “entrepreneurs for cures” to bring sense of urgency to the rest of the medical research community.

In late 2007, the Bonnie J. Addario Lung Cancer Foundation invited leading physicians, clinicians, scientists, researchers, representatives from pharmaceutical and biotech companies, venture capitalists, international investors, and Lung Cancer survivors to convene at the University of California Mission Bay Center. They were invited for one purpose—to answer the following Question: “If money for research and development was not a barrier and a true collaboration could be achieved, what would you do to improve lung cancer patient survival in the least amount of time and how much would it cost?” The Unanimous Answer: “We need a national Lung Cancer institute—an honest third-party broker—with a virtual specimen repository, connecting existing biobanks and researchers worldwide through a unique real-time IT platform and better means of collaboration.” In response, ALCMI was founded in 2008 by advanced stage lung cancer survivor Bonnie J. Addario and many supporters to positively and directly impact on lung cancer patient survival.

The Addario Lung Cancer Medical Institute (ALCMI) is a contractual consortium of academic- and community-based researchers designed to advance the understanding of disease biology and the development of significantly more effective treatment options. ALCMI links researchers via shared infrastructures and prioritized research programs including standardized biorepositories, data systems, contracts, study protocols and, as significantly, through ongoing collaboration discussions among the scientists.


ALCMI’s strategic research goals:
• Establish centralized research infrastructures

• Accelerate the understanding of the molecular/genetic causes and mechanisms

• Identify weaknesses in the lung cancer cell’s defenses to help develop effective, targeted therapies

• Deliver the right treatments to the right patients

To achieve these goals ALCMI has initiated or developed the following key initiatives

Shared Infrastructures

Collaborative Research Projects on Molecular and Correlative Sciences.

Scientific Leadership Board

To ensure that ALCMI achieves its mission, and to help guide the collaborative effort, ALCMI was fortunate to be able to assemble an executive scientific committee termed the Scientific Leadership Board (SLB). The SLB is comprised of a number of the world’s key opinion leaders in the field of lung cancer research and therapeutics development. To enable coordinated scientific planning and oversight, the SLB meets on a monthly basis developing new ALCMI collaborative research projects, evaluating ongoing projects and initiatives, and more broadly combining individuals strengths and insights of the scientists to accelerate the development of much more effective therapeutic options for lung cancer patients both today and in the near future.

Biorepository
Biorepositories (or biobanks) are “tissue libraries” where biospecimens are stored and made available for scientists to study for research purpose.

Addressing an unmet need, ALCMI has established a unique asset for the lung cancer research community—a centralized Biorepository of matched tumor tissues and blood samples uniformly collected an annotated with treatment and outcomes data. The CASTLE study is the inaugural project contributing to this exceptional resource, and ALCMI seeks external collaborators to fully leverage this lung cancer biorepository.

Data Systems
The ALCMI Data Repository enables centralized biological specimen tracking from initial collections through the course of treatment/outcomes to comply with regulations (such as GCPs and GLPs), satisfy study subject consent requirements, enhance scientific accuracy, and improve development efficiency.

Centralized Contracting
ALCMI acts as the lead negotiator for research agreements (contracts) internally and externally, thereby significantly reducing the inherent complexity of crafting (and thus accelerating) multi-party collaboration agreements.

ALCMI's Scientific Leadership Board (SLB) is the research consortium's executive scientific committee and is comprised of a number of the world's leading lung cancer researchers.  The SLB sets the organization’s scientific agenda, research priorities and develops/reviews the consortium's collaborative research projects including the use of any tissues and data collected under the CASTLE Network study.  

David Carbone, MD, PhD
Chair, Scientific Leadership Board

Dr. David Carbone is the Harold L. Moses Professor of Cancer Research, Professor of Medicine and Cancer Biology at the Vanderbilt University Medical Center and Director of the Experimental Therapeutics Program at the Vanderbilt-Ingram Cancer Center. He is also Director and Principal Investigator of the Vanderbilt Specialized Program of Research Excellence (SPORE) in Lung Cancer.

David Carbone graduated summa cum laude from Amherst College and received an MD and a PhD in Molecular Biology and Genetics at Johns Hopkins University. He then did an Internal Medicine internship and residency at The Johns Hopkins Hospital followed by a Medical Oncology fellowship at the National Cancer Institute (NCI). Dr. Carbone was appointed Assistant Professor at the University of Texas Southwestern Medical Center, and was later promoted to Associate Professor before being recruited to Vanderbilt University.

Dr. Carbone’s research interests, grant support and publications have been focused on lung cancer, and specifically lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms and gene therapy. Recent research directions include molecular profiling of lung cancers and preneoplasias, especially the use of mass spectrometry-based proteomics. He has over 100 peer-reviewed publications and review articles, has served on several NCI grant review panels, and has had continuous NCI funding since early in his career.

Dr. Carbone has served on organizing committees for both ASCO and AACR and he is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and serves on the Board of Scientific Counselors for the NCI.

Bonnie J. Addario
Lung Cancer Survivor & Founder, BJALCF & ALCMI

Bonnie is the Founder of ALCMI, and is also the Founder and Chair of the Bonnie J. Addario Lung Cancer Foundation (BJALCF), the nation’s largest philanthropy devoted exclusively to eradicating Lung Cancer. A seven-year Lung Cancer survivor, Bonnie is a visionary businesswoman with 25 years of experience in managing a large oil company and a commercial credit card networking company. A nationally recognized business leader, from 1997 to 2004 Bonnie was the President of both the Commercial Fueling Network and the Olympian Oil companies and was the first female President of the California Independent Oil Marketers. Through applying her business experience, extensive sales and marketing knowledge and insatiable passion to help patients, Bonnie has created two results-driven non-profits working collaboratively with the world’s thought leaders and researchers, pharmaceutical industry, and cancer patients to identify solutions and make timely and meaningful change through research, early detection, education, prevention, and treatment. Bonnie serves on the Sequoia Hospital Foundation Board, Vice Chair of the University of California, San Francisco Thoracic Cabinet, an advocate and member of Southwest Oncology Group (SWOG) Lung Committee, the 100th Member of Leadership Legacy Life, and was the 2008 Jefferson Award Winner for Public Service.

David R. Gandara, MD

Dr. David R. Gandara is a Professor of Medicine at the University of California, Davis School of Medicine, and serves as Associate Director of Clinical Research and Director of Thoracic Oncology at the University of California, Davis Cancer Center.

Dr. Gandara received his medical degree from the University of Texas Medical Branch in Galveston, followed by internship and residency at the Madigan Army Medical Center in Tacoma and a fellowship at the Letterman Army Medical Center Presidio of San Francisco.

Dr. Gandara is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology. He is currently principal investigator for a number of research projects in lung cancer, pharmacology trials at various phases, and Southwest Oncology Group trials. He is the principal investigator for a National Cancer Institute award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents.

Dr. Gandara is President of the International Association for the Study of Lung Cancer (IASLC) and serves on the board of directors. Dr. Gandara is chair of the Southwest Oncology Group (SWOG) Lung Committee, and co-chair of the NCI-directed Investigational Drug Steering Committee. He has written over 300 articles, book chapters, abstracts and editorials. He is editor-in-chief of Clinical Lung Cancer, serves on the editorial board of four oncology journals, and is a manuscript reviewer for eight additional journals. He served as secretary-treasurer and a member of the board of directors for the American Society of Clinical Oncology (ASCO). Dr. Gandara is a member of the Scientific Leadership Council in Lung Cancer.

David Jablons, MD

Dr. David M. Jablons is Professor and Chief of Thoracic Surgery at the University of California, San Francisco, and Ada Distinguished Professor of Thoracic Oncology at the UCSF Helen Diller Comprehensive Cancer Center, where he also serves as Program Leader of Thoracic Oncology.

Dr. Jablons received his undergraduate degree from Yale University and his medical degree from Albany Medical College of Union University. He has also trained at numerous highly-regarded institutions including Tufts-New England Medical Center, Oak Knoll Naval Hospital, the Surgery Branch of NCI, Cornell University Medical Center, New York Hospital/Memorial Sloan Kettering Cancer Center, and Brigham & Women’s Hospital.

Dr. Jablons established the UCSF/UC Davis Thoracic Oncology Conference, one of the oldest and longest running didactic conferences in the field. He also helped found the International Pan Pacific Lung Cancer Conference. He is a strong supporter of international efforts to expand lung cancer research, and helped start the China Clinical Trials Consortium (CCTC). He also co-founded the Bonnie J. Addario Lung Cancer Foundation and the Addario Lung Cancer Medical Institute.

Dr. Jablons leads a team of scientists developing molecularly targeted therapies for lung cancer and mesothelioma. Key research areas include the Wnt and Hedgehog (Hh) pathways, and stem cell signaling targets. The Thoracic Oncology Tissue Bank is one of the largest such repositories in the U.S. and serves as a hub for interdisciplinary collaboration. Dr. Jablons is also a principal investigator on two NIH R01 grants and has authored over 100 peer-reviewed research papers. In addition, he serves as a reviewer on several NIH study groups.

Pasi A. Jänne, MD, PhD

Dr. Pasi A. Jänne is an Associate Professor of Medicine at Harvard Medical School and Assistant Physician at the Dana Farber Cancer Institute in Boston, Massachusetts.

After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002 he earned a Masters Degree in clinical investigation from Harvard University.

Dr. Jänne’s research interests include investigation of oncogene mutations and how these correlate with clinical response to targeted therapies in lung cancer. He was one of the investigators who initially discovered EGFR mutations in 2004 and has subsequently studied their effect on clinical outcome of patients and on mechanisms of resistance. He has also worked on developing non-sequencing based technology to detect mutations in EGFR and other oncogenes. Dr. Jänne is a member of the Cancer and Leukemia Group B respiratory committee. He is also an active member of ASCO, AACR, ESMO and IASLC. He was elected to the American Society of Clinical Investigation in 2008.

Ite Laird-Offringa, PhD

Dr. Ite Laird-Offringa is an Associate Professor of Surgery and of Biochemistry and Molecular Biology at Norris Comprehensive Cancer Center at the University of Southern California (USC), Keck School of Medicine. She is also the Director of the Program in Biomedical and Biological Sciences at USC.

Dr. Laird-Offringa earned her Ph.D. from the University of Leiden, The Netherlands, and conducted postdoctoral work at Harvard Medical School. She joined the USC faculty in 1996. She is a member of many national and international professional and advocate societies, including the American Association for Cancer Research, the International Association for the Study of Lung Cancer, and the National Lung Cancer Partnership, and she serves as a reviewer on the NIH/NCI Cancer Genetics study section.

Dr. Laird-Offringa is committed to the development of better tools for early lung cancer detection. Her laboratory’s current research in lung cancer focuses on the identification of cancer-specific changes in antibodies and in DNA methylation, a reversible alteration of DNA that can affect gene expression. The obtained information is used for biomarker development and to gain insight into the sequential molecular steps that happen during the development of lung cancer. The Laird-Offringa laboratory is funded by two NIH R01 grants and by generous donations and grants from several private foundations and individuals. In her work, she collaborates with pathologists, oncologists, surgeons, epidemiologists and a variety of other scientists.

Harvey I. Pass, MD

Harvey I. Pass, MD is Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiology, and first Division Chief of General Thoracic Surgery at NYU School of Medicine. He joined NYU Medical Center in 2005 to lead the Division of Thoracic Surgery and Thoracic Oncology. His previous positions include Chief, Thoracic Oncology at the Karmanos Cancer Institute, and Head of the Thoracic Oncology Section of the National Cancer Institute (NCI) for the National Institutes of Health.

Dr. Pass received his B.A. from Johns Hopkins University and his M.D. from Duke University. He completed his surgical residency at Duke and University of Mississippi. He completed his residency in Cardiothoracic Surgery at the Medical University of South Carolina. Dr. Pass also completed a fellowship in Thoracic Oncology at NCI.

Dr. Pass has published over 300 manuscripts in peer-reviewed journals, including The New England Journal of Medicine regarding the discovery of osteopontin as a possible early detection biomarker for mesothelioma. He is an editor of Lung Cancer: Principles and Practice, Surgery: Basic Science and Clinical Evidence, Oncology: An Evidence Based Approach, and Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. Dr. Pass is Associate Editor for the Journal of Thoracic Oncology, Surgical Editor for Clinical Lung Cancer and a member of the editorial board for Clinical Cancer Research.

Dr. Pass is presently on the Board of Directors for the International Association for the Study of Lung Cancer, the International Mesothelioma Interest Group, the Lung Cancer Alliance, and the Mesothelioma Foundation.

Rafael Rosell, MD, PhD

Dr. Rafael Rosell is Scientific Director for Oncology at the Catalan Institute of Oncology, Chief of the Medical Oncology Service at Hospital Germans Trias i Pujol in Badalona, Chairman of Pangaea Biotech, SA and Professor at the University of Barcelona.

Dr. Rosell is the founder and President of the Spanish Lung Cancer Group (SLCG), Chairman of the IASLC 2005 World Conference on Lung Cancer, and Co-Chair of the 1st and 2nd IASLC-ESMO European Lung Cancer Conferences. He is an active member of the ESMO Educational Committee, and the EORTC Protocol Review Committee. He is on the Editorial Board of several peer-reviewed medical journals. Dr. Rosell has authored over 450 articles in peer-reviewed journals and given more than 600 presentations at conferences around the world.

Since the early 1990s, Dr. Rosell has been involved in the application of genetic research to the clinical setting. Recent translational research by Dr Rosell’s group has focused on chemosensitivity in relation to polymorphisms of DNA repair genes, methylation patterns in circulating DNA, and gene expression profiles in RNA. Dr. Rosell’s group is also involved in research on EGFR mutations and has implemented large-scale screening for EGFR mutations in newly-diagnosed lung cancer patients in Spain in order to select patients for treatment with EGFR inhibitors instead of chemotherapy as first-line treatment. In the SLCG’s ongoing trials in the adjuvant and the metastatic setting of NSCLC, customized chemotherapy and targeted therapy are being implemented as standard treatment.

Giorgio V. Scagliotti, MD, PhD

Dr. Scagliotti is Full Professor of Respiratory Medicine at the University of Torino. Dr. Scagliotti earned his medical degree and completed the postgraduate training in respiratory medicine, internal medicine, and medical oncology at the University of Torino. He is chief of the Thoracic Oncology Division at the S. Luigi Hospital, Orbassano (Torino) and Head of the Department of Clinical and Biological Sciences at University of Torino. He is also the Chairperson of the Postgraduate School in Respiratory Medicine at the same University.

Over the last 15 years Dr. Scagliotti’s research interests included experimental studies on basic and clinical applied research on lung cancer, including translational research. He has been and currently is the study coordinator of several European and international clinical trials on lung cancer chemotherapy and he has been a key investigator in several Italian studies investigating the role of chemotherapy in early stage non-small cell lung cancer. Dr. Scagliotti is a member of numerous scientific societies, including the Italian Society of Respiratory Medicine, the European Respiratory Society, the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. From 2002 to 2005 he was member of the International Affair Committee of the American Society of Clinical Oncology and from 2003-07 Executive Board member of the International Association for the Study of Lung Cancer. He served on the Publication Committee (2005-08) and in Program Committee of the American Society of Clinical Oncology in the period 2005-07. Dr. Scagliotti is a manuscript reviewer for 11 scientific journals. He currently serves on the editorial boards of Critical Review in Oncology and Hematology, and Oncology News. He is Associate Editor for Journal of Thoracic Oncology and International Editor for Clinical Lung Cancer. He is the author or co-author of more than 180 publications in peer-reviewed journals and he is the International Editor of the 4th Edition of the book “Lung Cancer : Principles and practice”

Jean-Charles Soria, MD, PhD

Jean-Charles Soria is a Professor of Medecine and Medical Oncology at South-Paris University. He is a tenure-track and full time cancer specialist at Institut Gustave Roussy. Dr Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a PhD degree in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA.

Professor Soria is currently head of the phase I program at Institut Gustave Roussy and is a member of the lung cancer unit with a focus on targeted therapies. His main research interest are: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer. He is also involved in translational research aspects related to tumor progression notably in lung cancer models (INSERM unit 981). Dr Soria was a member of ESMO executive committee from 2008 to 2009, and serves as an ASCO committee member since 2006. He has contributed to over 230 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, the Journal of the National Cancer Institute, and the Journal of Clinical Oncology.

The all-voluntary Board of Directors is responsible for ensuring the excellent management (including fiscal performance/accountability) of ALCMI, establishes and/or approves policies and procedures, and generally oversees the business and affairs of the organization.

Tony Addario, Chair

Tony Addario, formerly an executive in the computer networking industry, is Chairman of the Board and interim CEO of the Addario Lung Cancer Medical Institute (ALCMI). Prior to helping launch ALCMI, Tony spent a successful career helping build several technology leaders and is on the advisory board for several Silicon Valley start-ups. He’s a retired vice president for Customer Support and Services for both Bay Networks and Juniper Networks. He also spent several years as a senior technical advisor on several of NASA’s programs including the Manned Space Flight Network. He has served on several boards including the Thunderbird Lodge Preservation Society in Lake Tahoe, the Green Hills Country Club in Millbrae CA and the Computer Science Advisory Board for Sierra Nevada College, Incline Village NV. Tony and his wife Bonnie J. Addario have been major supporters of the Bonnie J Addario Lung Cancer Foundation, ALCMI, Sequoia Hospital in San Carlos CA, the UCSF Comprehensive Cancer Center and the Brain Science Foundation. Tony is a Philadelphia, PA native and Temple University graduate.

Scott Santarella – Vice Chair
President & CEO, BJALCF

Scott Santarella, former President and CEO of the American Lung Association in New York and former COO of the Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) recently joined the Bonnie J. Addario Lung Cancer Foundation as President and CEO.

Mr. Santarella has more than 20 years of experience as a senior executive with a proven track record in innovative marketing, successful management of fundraising, and raising awareness for underfunded diseases and causes. His knowledge of science and research combined with the highest regard to ethics and constituent service has driven his successful track record of raising more than $250 million in his previous leadership roles.

Bonnie J. Addario
Lung Cancer Survivor & Founder, BJALCF & ALCMI

Bonnie is the Founder of ALCMI, and is also the Founder and Chair of the Bonnie J. Addario Lung Cancer Foundation (BJALCF), the nation’s largest philanthropy devoted exclusively to eradicating Lung Cancer. A seven-year Lung Cancer survivor, Bonnie is a visionary businesswoman with 25 years of experience in managing a large oil company and a commercial credit card networking company. A nationally recognized business leader, from 1997 to 2004 Bonnie was the President of both the Commercial Fueling Network and the Olympian Oil companies and was the first female President of the California Independent Oil Marketers. Through applying her business experience, extensive sales and marketing knowledge and insatiable passion to help patients, Bonnie has created two results-driven non-profits working collaboratively with the world’s thought leaders and researchers, pharmaceutical industry, and cancer patients to identify solutions and make timely and meaningful change through research, early detection, education, prevention, and treatment. Bonnie serves on the Sequoia Hospital Foundation Board, Vice Chair of the University of California, San Francisco Thoracic Cabinet, an advocate and member of Southwest Oncology Group (SWOG) Lung Committee, the 100th Member of Leadership Legacy Life, and was the 2008 Jefferson Award Winner for Public Service.

Sam Bain
Founder, CEO & Managing Director, Bainco International Investors

Sam founded Bainco International Investors in 1987, leads the direction of the firm’s investments and strategy, and serves on the board of several of Bainco’s private equity investment partnerships. Prior to founding Bainco, Sam was a Senior Vice President at Donaldson, Lufkin & Jenrette, serving high net-worth individuals and institutions, and spent several years as a Chairman’s Club wealth Advisor at Merrill Lynch. He is a member of the Board of Overseers for Beth Israel Deaconess Medical Center; a Trustee of St. Johnsbury Academy; a Trustee of the University of Vermont.

Brock Siegel, PhD
Angel Investor; Fmr COO, Illumina/Solexa Inc

Dr. Siegel is a veteran member of the life science community, specializing in commercializing R&D technology, building operations, launching scalable businesses and acquiring new businesses in regulated life sciences diagnostics and forensics, in particular DNA sequencing.

Academically trained in bioorganic chemistry, Dr. Siegel focused on the elucidation of enzyme mechanisms via synthetic organic model systems, an early entry into synthetic biology. He holds a Bachelor of Science from Syracuse University, a Doctorate of Philosophy from the University of Illinois, completed his post-doctoral work at Columbia University, and is a former Professor at the University of Minnesota.

Currently, Dr. Siegel is an investment member of Life Science Angels, where he is also on the Board of Directors and co-chairs the Device Screening Group. He serves on the Board of Directors of Rapid Diagnostek Inc, the Advisory Boards of ruubix diagnostics and moleculo Inc., and the Board of Visitors of Syracuse University. He mentors young founders in the Burrill-UCSF “Ideas to IPO” program and is an investment advisor for UCSF’s Mission Bay Capital Fund. He has been named a Distinguished Alumni by the University of Illinois.

Bruce Gellman
Cancer Survivor, Executive, communications industry

Bruce Gellman is a 30-year veteran of the computer industry. Beginning his career in the New York Financial District at Burroughs Corporation [mainframe computers] in the 70’s, large enterprise networks in the 80’s, high-speed Internet access and VOIP technologies in the 90’s, social networking and most recently an adviser, investor and mentor focused on emerging cleantech technologies. Bruce has had key roles in several start-ups companies including two that had successful public offerings. Bruce is a cancer survivor.

Pankaj Patel
Vice President of Marketing, Cisco Systems

Pankaj Patel, Senior Vice President Engineering and General Manager, Service Provider Business co-leads Cisco’s engineering organization and is General Manager of its Service Provider Business. Cisco’s engineering organization consists of over 24,000 global employees and Patel is responsible for the development, strategy and execution of its $32 billion product portfolio. Patel’s focus is on core routing, mobility, video and cloud/managed services, as well as architectures for business transformation. In addition, Patel has general manager responsibility for the company’s go-to-market strategies and customer value propositions for its $10 billion service provider business.

Steven Young
President and Chief Operating Officer

Mr. Young assumed the role of President & Chief Operating Officer of the Addario Lung Cancer Medical Institute in September 2008. He has nearly 20 years experience in clinical and laboratory research and most recently served as the Executive Director of the Multiple Myeloma Research Consortium (MMRC), a non-profit corporation based in Connecticut that developed and implemented novel biorepositories, data systems, and scientific cores linking investigators and clinicians from academia, the community, and the biopharmaceutical industry. Prior to his position with the MMRC, Mr. Young directed the development and successful launches of several clinical research for-profit business models and served as Director of National Institutes of Health-funded General Clinical Research Centers at Mount Sinai School of Medicine and Cornell University College of Medicine, both in New York.

Alicia Sable-Hunt RN, MBA
Consultant, Director of Clinical Operations

Ms. Hunt has invested over 16 years working in the fields of nursing and clinical research, specializing in oncology and transplant patient populations. After years of bedside nursing, she transitioned to the management of oncology clinical trials for academic institutions. Ms. Hunt’s formal background and experience enabled her to develop the clinical operations of a disease-specific non-profit, including an oncology clinical trials program and disease-specific biorepository. She works from the premise that biobanking is the foundation for drug development. In an effort to see this model become reality, Ms. Hunt founded a life science consulting firm to fully support non-profit organizations developing translational medicine programs in order to drive drug development in the direction of their particular disease. As a result of Ms. Hunt’s contributions in the biobanking industry, she has been named FasterCure’s Who’s Who of Biobanking.